We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.64B
$3.62M 1%
+193,955
New +$3.21M
ARGX icon
27
argenx
ARGX
$53.8B
$3.59M 0.99%
4,918
+1,330
+37% +$1.04M
PTGX icon
28
Protagonist Therapeutics
PTGX
$9.06B
$3.57M 0.99%
33,852
-39,693
-54% -$3.51M
PALI icon
29
Palisade Bio
PALI
$342M
$3.53M 0.98%
2,019,326
+719,295
+55% +$1.31M
DFTX
30
Definium Therapeutics
DFTX
$5.88B
$3.51M 0.97%
+185,856
New +$3.15M
NRIX icon
31
Nurix Therapeutics
NRIX
$2.4B
$3.51M 0.97%
+226,546
New +$3.76M
AXSM icon
32
Axsome Therapeutics
AXSM
$11.8B
$3.45M 0.95%
20,437
+9,306
+84% +$1.61M
IVA
33
Inventiva
IVA
$1.09B
$3.42M 0.94%
+615,666
New +$3.75M
DYN icon
34
Dyne Therapeutics
DYN
$3.92B
$3.32M 0.92%
182,929
+123,286
+207% +$2.13M
APGE icon
35
Apogee Therapeutics
APGE
$10.1B
$3.01M 0.83%
35,761
-53,468
-60% -$3.88M
GHRS icon
36
GH Research
GHRS
$1.97B
$3M 0.83%
213,212
-27,312
-11% -$419K
DNTH icon
37
Dianthus Therapeutics
DNTH
$5.77B
$2.99M 0.82%
35,587
-12,897
-27% -$747K
MAZE
38
Maze Therapeutics
MAZE
$1.56B
$2.98M 0.82%
99,850
-70,503
-41% -$3.11M
ERAS icon
39
Erasca
ERAS
$6.65B
$2.93M 0.81%
+181,069
New +$2.14M
EWTX icon
40
Edgewise Therapeutics
EWTX
$4.28B
$2.9M 0.8%
91,931
-79,206
-46% -$2.28M
ELVN icon
41
Enliven Therapeutics
ELVN
$3.8B
$2.87M 0.79%
73,102
-9,434
-11% -$261K
XENE icon
42
Xenon Pharmaceuticals
XENE
$6.6B
$2.85M 0.79%
+49,050
New +$2.26M
CLDX icon
43
Celldex Therapeutics
CLDX
$2.77B
$2.84M 0.78%
89,397
+37,592
+73% +$1.02M
VERA icon
44
Vera Therapeutics
VERA
$2.76B
$2.79M 0.77%
+69,241
New +$2.98M
PHVS icon
45
Pharvaris
PHVS
$2.44B
$2.76M 0.76%
97,866
-64,504
-40% -$1.72M
VRDN icon
46
Viridian Therapeutics
VRDN
$1.99B
$2.63M 0.73%
134,229
-238,243
-64% -$7.08M
ALKS icon
47
Alkermes
ALKS
$8.79B
$2.59M 0.71%
73,189
+46,788
+177% +$1.45M
ALMS
48
Alumis Inc
ALMS
$3.65B
$2.49M 0.69%
+112,929
New +$2.82M
MSFT icon
49
Microsoft
MSFT
$2.93T
$2.39M 0.66%
6,457
-80
-1% -$33.5K
EYPT icon
50
EyePoint Inc
EYPT
$1.12B
$2.36M 0.65%
+183,037
New +$2.74M
1
2
3 4 5

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.